N

Nuclera Tech Stack

Benchtop protein screening platform using cell-free expression and microfluidics

Biotechnology Research Cambridge, Cambridgeshire 51–200 employees Founded 2013 Privately Held

Nuclera operates a hardware-software platform for multiplex protein screening, combining cell-free expression systems with digital microfluidics. The tech stack (SnapGene, Benchling, Python, TypeScript, GitLab CI/CD) reflects a biotech company building both bench instruments and supporting software. Active hiring across product and research—alongside projects spanning antibody workflows, synthetic biology, and platform capabilities—signals expansion beyond core protein discovery into adjacent applications; simultaneous investment in logistics and storage infrastructure indicates scaling from pilot deployments to revenue production.

Tech Stack 11 technologies

Core StackTypeScript Python Playwright GitLab CI/CD Linux SnapGene Benchling TestRail Git bash ssh

What Nuclera Is Building

◆Challenges

Optimizing platform capabilities
Optimising shipping routes and costs
Reducing transit bottlenecks
Maintaining inventory integrity
Antibody discovery workflow challenges
Ensuring software quality for eprotein discovery platform

▲Active Projects

Productization of antibody-relevant workflows
Antibody applications roadmap
New capabilities of our platform
Pilot-to-revenue transition
Ngs library prep
Synthetic biology applications
Build the nuclera eprotein discovery instrument
Optimising shipping routes and costs
Improving logistics sops
Organising temperature controlled storage

Hiring Activity

Accelerating9 roles · 6 in 30d

Department

Product

4

Research

2

Engineering

1

Manufacturing

1

Operations

1

Seniority

Manager

5

Mid

4

Company intelligence

Find more companies like Nuclera by tech stack, pain points and active projects

Get started free

About Nuclera

Nuclera manufactures and sells the eProtein Discovery system, an automated benchtop instrument that enables researchers to perform protein screening, characterization, and small-scale expression in-house in days. Founded in 2013 by University of Cambridge PhD students, the company operates from Cambridge, UK and Boston, MA, with over 100 employees. The platform targets life-science research labs seeking faster access to difficult proteins (including membrane proteins) without outsourcing, reducing lead times and enabling iterative design cycles. Current work spans productization of antibody workflows, synthetic biology applications, and instrument optimization, while operational focus includes shipping logistics and inventory management for biological sample handling.

HeadquartersCambridge, Cambridgeshire

Company Size51–200 employees

Founded2013

Hiring MarketsUnited Kingdom, United States

Frequently Asked Questions

What is Nuclera's eProtein Discovery system?

An automated benchtop platform combining cell-free protein expression, digital microfluidics, and multiplex screening data to enable researchers to perform protein discovery, characterization, and production in-house within days, including difficult targets like membrane proteins.

What is Nuclera's tech stack?

SnapGene and Benchling for molecular design; Python and TypeScript for backend/frontend; GitLab CI/CD for deployment; TestRail for QA; Linux, bash, and ssh for infrastructure.